Litcius/Paper detail

Inhibition of <i>Toxoplasma gondii</i> by 1,2,4-triazole-based compounds: marked improvement in selectivity relative to the standard therapy pyrimethamine and sulfadiazine

Lidia Węglińska, Adrian Bekier, Nazar Trotsko, Barbara Kaproń, Tomasz Plech, Katarzyna Dzitko, Agata Paneth

2022Journal of Enzyme Inhibition and Medicinal Chemistry15 citationsDOIOpen Access PDF

Abstract

properties to advance into preclinical development; it showed ability to cross the BBB, did not induce genotoxic and haemolytic changes in human cells, and as well as it was characterised by low cellular toxicity.

Topics & Concepts

SulfadiazinePyrimethamineToxoplasma gondiiPharmacologySelectivityChemistryToxoplasmosisIC50TriazoleDrugCombinatorial chemistryStereochemistryIn vitroBiochemistryPlasmodium falciparumMedicineVirologyAntibioticsImmunologyOrganic chemistryMalariaAntibodyCatalysisToxoplasma gondii Research StudiesSynthesis and Characterization of Heterocyclic CompoundsSynthesis and Biological Evaluation
Inhibition of <i>Toxoplasma gondii</i> by 1,2,4-triazole-based compounds: marked improvement in selectivity relative to the standard therapy pyrimethamine and sulfadiazine | Litcius